


Drug Development Program (DDP) Biomarker Laboratory

Formerly AMPL, DDP has core technologies in cytomics, genomics and pharmacokinetics for the molecular profiling of tumour samples in clinical and preclinical studies.



Service Department(s): Research Communications

Overview

- Added to our competencies in cytomics/genomics/pharmacokinetics, we offer specialized consultation biomarker development within the realm of clinical study and research program protocols
- We have processed specimens for clinical trials conducted by the Princess Margaret Cancer Centre Drug Development Program (DDP), the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and industry sponsored projects

The Co-Directors of the facility are:

- Dr. [Eric Chen](#)
 - Dr. [Suzanne Kamel-Reid](#)
 - Dr. [David Hedley](#)
 - Dr. [Geoffrey Liu](#)
 - Dr. [Malcolm Moore](#)
 - Dr. Jeremy Squire
 - Dr. [Lillian Siu](#)
 - Dr. [Ming-Sound Tsao](#)
-

Unique Capacities

We provide a continuum of quality control procedures starting from specimen collection to preparation & analysis.

Services

Cytomics

- Tissue preparation, tissue microarray construction, immunolabelling
- ELISA
- R&D flow cytometry, single-cell signal activation analysis

Genomics

- FISH
- Gene mutations & single nucleotide polymorphisms (sequencing, real-time qPCR)

Pharmacokinetics

- HPLC analysis of blood and tissue samples

Using the Facility

- Accessible to internal, external-academic and external customers
- Research Ethics Board ([REB](#)) documents must accompany projects using human specimens and meet UHN REB standards

Usage Arrangements

- Fee for service – customizable work process
- Consultation for study design
- Method development & optimization
- Sample collection, preparation & analysis

Contacts

[Dr. Nhu-An Pham](#)

Manager